drugset / Trial / NCT01388517

Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba

NCT01388517

RandomizedParallel-groupDouble-blindTreatment

Summary

Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, trend to relapse and aesthetic impact. Currently, no treatment is widely accepted. The objective is to assess the calcitriol and tacrolimus ointment efficacy in the treatment of PA compared with petrolatum. Twenty lesions on the face greater than 3 cm, in individuals of phototype IV-V, aged 3-18 years are going to be randomly assigned to receive petrolatum, calcitriol, and tacrolimus twice daily. No photoprotection is going to be indicated, and hygienic habits will not be modified. Patients will be evaluated at baseline and for 9 weeks, by means of Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.

Timeline

Start
2008-01
Primary completion
2010-08
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcitriol Small molecule 0.0003 % Topical
Comparator Tacrolimus Small molecule 0.1 % Topical

Indications